384 related articles for article (PubMed ID: 19382366)
1. FDA notifications. FDA grants approval for raltegravir.
AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
[No Abstract] [Full Text] [Related]
2. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
[No Abstract] [Full Text] [Related]
3. FDA notifications. Raltegravir indication extended for treatment-naive patients.
AIDS Alert; 2009 Aug; 24(8):93. PubMed ID: 19705587
[No Abstract] [Full Text] [Related]
4. FDA notifications. FDA draft guidance on Hepatitis C/HIV coinfection.
AIDS Alert; 2010 Nov; 25(11):129-30. PubMed ID: 21128355
[No Abstract] [Full Text] [Related]
5. [CROI 2012: updates on raltegravir].
MMW Fortschr Med; 2012 May; 154 Suppl 1():41. PubMed ID: 22916600
[No Abstract] [Full Text] [Related]
6. FDA notifications. Reyataz is approved for HIV treatment.
AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309
[TBL] [Abstract][Full Text] [Related]
7. FDA notifications. Changes to ART guidelines detailed by the FDA.
AIDS Alert; 2008 Mar; 23(3):33-4. PubMed ID: 18663777
[No Abstract] [Full Text] [Related]
8. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
9. Clinicians debate antiretroviral tactics and toxicities, resistance testing, and hepatitis virus coinfection. IAPAC sessions 2002 - May 16-17, 2002.
Mascolini M
IAPAC Mon; 2002 Jul; 8(7):190-201. PubMed ID: 12154789
[No Abstract] [Full Text] [Related]
10. Effects of omeprazole on plasma levels of raltegravir.
Iwamoto M; Wenning LA; Nguyen BY; Teppler H; Moreau AR; Rhodes RR; Hanley WD; Jin B; Harvey CM; Breidinger SA; Azrolan N; Farmer HF; Isaacs RD; Chodakewitz JA; Stone JA; Wagner JA
Clin Infect Dis; 2009 Feb; 48(4):489-92. PubMed ID: 19143531
[TBL] [Abstract][Full Text] [Related]
11. Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients.
Cattaneo D; Ripamonti D; Gervasoni C; Landonio S; Meraviglia P; Baldelli S; Cozzi V; Fucile S; Clementi E
J Clin Pharmacol; 2012 Mar; 52(3):440-5. PubMed ID: 21383337
[TBL] [Abstract][Full Text] [Related]
12. FDA notifications. Accelerated approval for raltegravir tablets.
AIDS Alert; 2007 Dec; 22(12):143-4. PubMed ID: 18411485
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
Zhu L; Butterton J; Persson A; Stonier M; Comisar W; Panebianco D; Breidinger S; Zhang J; Bertz R
Antivir Ther; 2010; 15(8):1107-14. PubMed ID: 21149917
[TBL] [Abstract][Full Text] [Related]
14. FDA notifications. FDA postpones CCR5 Antagonist Review Group meeting.
AIDS Alert; 2006 Jan; 21(1):11-2. PubMed ID: 16470945
[No Abstract] [Full Text] [Related]
15. FDA notifications. Revised guidelines for pregnant women.
AIDS Alert; 2007 Dec; 22(12):141. PubMed ID: 18411483
[No Abstract] [Full Text] [Related]
16. Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis?
Gervasoni C; Riva A; Impagnatiello C; Galli M; Cattaneo D
Clin Infect Dis; 2013 Aug; 57(3):480-1. PubMed ID: 23616494
[No Abstract] [Full Text] [Related]
17. FDA notifications. FDA revises Baraclude labeling for HIV patients.
AIDS Alert; 2007 Sep; 22(9):103-4. PubMed ID: 18415955
[No Abstract] [Full Text] [Related]
18. FDA notifications. Pediatric HIV infection guidelines for use of ARTs are revised.
AIDS Alert; 2008 Apr; 23(4):46-7. PubMed ID: 19255980
[No Abstract] [Full Text] [Related]
19. 3TC receives full approval.
Grodeck B; Vazquez E
Posit Aware; 1997; 8(3):11. PubMed ID: 11364417
[TBL] [Abstract][Full Text] [Related]
20. Treatment activists meet with the FDA.
Huff B
GMHC Treat Issues; 2003 Nov; 17(11):10-1. PubMed ID: 14717107
[No Abstract] [Full Text] [Related]
[Next] [New Search]
